Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02163226 · ClinicalTrials.gov registry record · Phase 2

A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms

A Phase 2 study, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 2
Development phase
167
Enrollment target

NCT02163226: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.

NCT02163226 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 167 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02163226, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
167 participants
Enrollment target

Study Summary

The goal of this clinical research study is to learn if 1 large dose of radiation therapy is better at controlling pain from cancer that has spread to the bones than 10 smaller doses of radiation. Researchers also want to learn if 1 large dose of radiation therapy can help decrease the use of drugs to control the pain, and if it can help to control the disease.

Interventions

  • BEHAVIORAL Questionnaire
  • RADIATION Hypofractionated Radiation Treatment
  • RADIATION One Radiation Treatment

Trial Details

FieldValue
Enrollment Target 167 participants
Start Date 2014-08-06
Est. Completion 2020-09-02
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT02163226

The ClinicalTrials.gov registry entry for NCT02163226 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Questionnaire is the first listed.

NCT02163226 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02163226 about?

NCT02163226 is a clinical study titled "A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms". The goal of this clinical research study is to learn if 1 large dose of radiation therapy is better at controlling pain from cancer that has spread to the bones than 10 smaller doses of radiation. Researchers also want to learn if 1 large dose of radiation therapy can help decrease the use of drugs ...

What is the current status of trial NCT02163226?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2014-08-06. Estimated completion is 2020-09-02.

What interventions are being tested in trial NCT02163226?

The interventions under investigation include: Questionnaire (BEHAVIORAL), Hypofractionated Radiation Treatment (RADIATION), One Radiation Treatment (RADIATION).

Who is sponsoring clinical trial NCT02163226?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.